Caribou Biosciences, Inc. (CRBU): Submission of Matters to a Vote of Security Holders
Caribou Biosciences, Inc. (CRBU) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. crbu-20260617 FALSE 0001619856 0001619856 2026-06-17 2026-06-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________________________ FORM 8-K ________________________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the
How this was made
The 30-second read
Why it matters
The newest disclosed facts are the vote tallies: three Class II directors were elected; Deloitte & Touche LLP was ratified as independent auditor; Proposal 3 (officer exculpation charter amendment) was not approved; the meeting was approved to be adjourned if needed, but the company did not adjourn after Proposal 3 failed.
Market read
This is a governance/proxy-results disclosure; it is unlikely to drive a fundamental repricing absent additional catalysts.
What to watch
Director election and auditor ratification passed, which may offset any negative read-through from the failed charter amendment; the filing provides no detail on why Proposal 3 failed.
Background
Caribou Biosciences filed an 8-K (Item 5.07) summarizing final results from its June 17, 2026 annual stockholders meeting, referencing a May 1, 2026 definitive proxy statement.
Ticker impact
CRBU reported 2026 annual meeting voting results, including election of three directors and rejection of a charter exculpation amendment.
Limited near-term impact; any reaction likely modest and governance-focused.
The 8-K is a routine disclosure of proxy vote tallies (director election, auditor ratification, and a failed charter amendment). It does not include new guidance, trial results, financing, or enforcement actions.
Market effects
Minimal—no sector-wide regulatory/clinical/financing signal is disclosed.
Minimal—US-listed biotech governance mechanics only.
Minimal—no cross-border deal or regulatory action mentioned.
Counterpoint
The failed exculpation amendment could be interpreted as shareholder resistance to management-friendly governance changes, potentially influencing future proxy negotiations.
Key entities
- issuerCaribou Biosciences, Inc.
Subject of the SEC 8-K; reported annual meeting voting results and proposal outcomes.
- auditorDeloitte & Touche LLP
Ratified by stockholders as independent registered public accounting firm for fiscal year ending Dec. 31, 2026.
- directorsAndrew Guggenhime, David Johnson, Nancy Whiting
Elected as Class II directors in the annual meeting vote.
